Dr Reddy’s secures thrombosis drug rights in $17.5m deal

27-11-2015

Dr Reddy’s secures thrombosis drug rights in $17.5m deal

Svetlana Lukienko / Shutterstock.com

Indian pharmaceutical company Dr Reddy’s has agreed a deal to buy global intellectual property rights to a generic version of GSK’s deep vein thrombosis (DVT) treatment Arixtra (fondaparinux sodium) as part of a $17.5 million deal with a partner company.


Dr. Reddy’s Laboratories, GSK, Alchemia, patent, fondaparinux sodium

LSIPR